O-27 - Using high-specific activity Samarium-153 for the development of [153Sm] Sm DOTA-TATE for targeted radionuclide therapy of neuroendocrine tumors

Koen Vermeulen; Michiel Van de Voorde; Noami Daems; Charlotte Duchemin; Sunay Rodriguez Pérez; Melissa Crabbé; Heinke Reinhard; Bernard Ponsard; Lorain Geenen; Julie Nonnekens; Laura Lambert; Cyril Bernerd; Andrew Burgoyne; Thomas Elias Cocolios; Thierry Stora; Maarten Ooms

doi:10.1016/S0969-8051(22)00085-3

O-27 - Using high-specific activity Samarium-153 for the development of [153Sm] Sm DOTA-TATE for targeted radionuclide therapy of neuroendocrine tumors

Koen Vermeulen
, Michiel Van de Voorde
, Noami Daems
, Charlotte Duchemin
, Sunay Rodriguez Pérez
, Melissa Crabbé
, Heinke Reinhard
, Bernard Ponsard
, Lorain Geenen
, Julie Nonnekens
, Laura Lambert
, Cyril Bernerd
, Andrew Burgoyne
, Thomas Elias Cocolios
, Thierry Stora
, Maarten Ooms

TRT-Radiochemistry

Research output › peer-review

Abstract

Samarium-153 is a promising radionuclide for targeted radionuclide therapy (TRNT) because of its highly favorable decay characteristics. 153Sm has a half-life of 1.93 days and emits Beta- particles (705 keV, 635 keV) which are suitable for therapy. 153Sm also emits Y photons (103 keV) with characteristics that allow SPECT imaging, making 153Sm a high-potential theranostic radioisotope.
The full potential of 153Sm is currently not being exploited because of the limited specific activity available as a result of its carrier-added production route (152Sm(n,Y)153Sm). In our previous work, we tried to remedy this by applying mass separation after the neutron activation to produce 153Sm with a much higher specific activity [1]. In this study, we use high specific activity (HSA) samarium-153 for the radiolabeling of the somatostatin analogue DOTA-TATE. This study
reports the radiolabeling and early biological evaluation of [153Sm] Sm-DOTA-TATE.

Original language	English
Pages (from-to)	S20
Number of pages	1
Journal	Nuclear Medicine and Biology
Volume	108-109
Issue number	Supplement
DOIs	https://doi.org/10.1016/S0969-8051(22)00085-3
State	Published - May 2022

Access to Document

10.1016/S0969-8051(22)00085-3License: Unspecified

Cite this

Vermeulen, K., Van de Voorde, M., Daems, N., Duchemin, C., Rodriguez Pérez, S., Crabbé, M., Reinhard, H., Ponsard, B., Geenen, L., Nonnekens, J., Lambert, L., Bernerd, C., Burgoyne, A., Cocolios, T. E., Stora, T., & Ooms, M. (2022). O-27 - Using high-specific activity Samarium-153 for the development of [153Sm] Sm DOTA-TATE for targeted radionuclide therapy of neuroendocrine tumors. Nuclear Medicine and Biology, 108-109(Supplement), S20. https://doi.org/10.1016/S0969-8051(22)00085-3

@article{dc6b5bffb53b4bf0b2a6779f64584df7,

title = "O-27 - Using high-specific activity Samarium-153 for the development of [153Sm] Sm DOTA-TATE for targeted radionuclide therapy of neuroendocrine tumors",

abstract = "Samarium-153 is a promising radionuclide for targeted radionuclide therapy (TRNT) because of its highly favorable decay characteristics. 153Sm has a half-life of 1.93 days and emits Beta- particles (705 keV, 635 keV) which are suitable for therapy. 153Sm also emits Y photons (103 keV) with characteristics that allow SPECT imaging, making 153Sm a high-potential theranostic radioisotope. The full potential of 153Sm is currently not being exploited because of the limited specific activity available as a result of its carrier-added production route (152Sm(n,Y)153Sm). In our previous work, we tried to remedy this by applying mass separation after the neutron activation to produce 153Sm with a much higher specific activity [1]. In this study, we use high specific activity (HSA) samarium-153 for the radiolabeling of the somatostatin analogue DOTA-TATE. This study reports the radiolabeling and early biological evaluation of [153Sm] Sm-DOTA-TATE. ",

keywords = "DOTA-TATE, Targeted radionuclide therapy",

author = "Koen Vermeulen and \{Van de Voorde\}, Michiel and Noami Daems and Charlotte Duchemin and \{Rodriguez P{\'e}rez\}, Sunay and Melissa Crabb{\'e} and Heinke Reinhard and Bernard Ponsard and Lorain Geenen and Julie Nonnekens and Laura Lambert and Cyril Bernerd and Andrew Burgoyne and Cocolios, \{Thomas Elias\} and Thierry Stora and Maarten Ooms",

note = "Score=10",

year = "2022",

month = may,

doi = "10.1016/S0969-8051(22)00085-3",

language = "English",

volume = "108-109",

pages = "S20",

journal = "Nuclear Medicine and Biology",

issn = "0969-8051",

publisher = "Elsevier Inc.",

number = "Supplement",

}

Vermeulen, K , Van de Voorde, M , Daems, N, Duchemin, C, Rodriguez Pérez, S , Crabbé, M, Reinhard, H, Ponsard, B , Geenen, L, Nonnekens, J, Lambert, L, Bernerd, C, Burgoyne, A, Cocolios, TE, Stora, T & Ooms, M 2022, 'O-27 - Using high-specific activity Samarium-153 for the development of [153Sm] Sm DOTA-TATE for targeted radionuclide therapy of neuroendocrine tumors', Nuclear Medicine and Biology, vol. 108-109, no. Supplement, pp. S20. https://doi.org/10.1016/S0969-8051(22)00085-3

TY - JOUR

T1 - O-27 - Using high-specific activity Samarium-153 for the development of [153Sm] Sm DOTA-TATE for targeted radionuclide therapy of neuroendocrine tumors

AU - Vermeulen, Koen

AU - Van de Voorde, Michiel

AU - Daems, Noami

AU - Duchemin, Charlotte

AU - Rodriguez Pérez, Sunay

AU - Crabbé, Melissa

AU - Reinhard, Heinke

AU - Ponsard, Bernard

AU - Geenen, Lorain

AU - Nonnekens, Julie

AU - Lambert, Laura

AU - Bernerd, Cyril

AU - Burgoyne, Andrew

AU - Cocolios, Thomas Elias

AU - Stora, Thierry

AU - Ooms, Maarten

N1 - Score=10

PY - 2022/5

Y1 - 2022/5

N2 - Samarium-153 is a promising radionuclide for targeted radionuclide therapy (TRNT) because of its highly favorable decay characteristics. 153Sm has a half-life of 1.93 days and emits Beta- particles (705 keV, 635 keV) which are suitable for therapy. 153Sm also emits Y photons (103 keV) with characteristics that allow SPECT imaging, making 153Sm a high-potential theranostic radioisotope. The full potential of 153Sm is currently not being exploited because of the limited specific activity available as a result of its carrier-added production route (152Sm(n,Y)153Sm). In our previous work, we tried to remedy this by applying mass separation after the neutron activation to produce 153Sm with a much higher specific activity [1]. In this study, we use high specific activity (HSA) samarium-153 for the radiolabeling of the somatostatin analogue DOTA-TATE. This study reports the radiolabeling and early biological evaluation of [153Sm] Sm-DOTA-TATE.

AB - Samarium-153 is a promising radionuclide for targeted radionuclide therapy (TRNT) because of its highly favorable decay characteristics. 153Sm has a half-life of 1.93 days and emits Beta- particles (705 keV, 635 keV) which are suitable for therapy. 153Sm also emits Y photons (103 keV) with characteristics that allow SPECT imaging, making 153Sm a high-potential theranostic radioisotope. The full potential of 153Sm is currently not being exploited because of the limited specific activity available as a result of its carrier-added production route (152Sm(n,Y)153Sm). In our previous work, we tried to remedy this by applying mass separation after the neutron activation to produce 153Sm with a much higher specific activity [1]. In this study, we use high specific activity (HSA) samarium-153 for the radiolabeling of the somatostatin analogue DOTA-TATE. This study reports the radiolabeling and early biological evaluation of [153Sm] Sm-DOTA-TATE.

KW - DOTA-TATE

KW - Targeted radionuclide therapy

UR - https://ecm.sckcen.be/OTCS/llisapi.dll/overview/52601656

U2 - 10.1016/S0969-8051(22)00085-3

DO - 10.1016/S0969-8051(22)00085-3

M3 - Special issue

SN - 0969-8051

VL - 108-109

SP - S20

JO - Nuclear Medicine and Biology

JF - Nuclear Medicine and Biology

IS - Supplement

ER -